| Fund Description |
| The Loncar China BioPharma ETF trades on Nasdaq under the symbol CHNA. It is made of up a basket of companies that are leading China s biotech revolution. With a focus on innovators, the fund contains globally listed pharmaceutical companies, biotech companies, drug manufacturers, diagnostics companies, wholesalers, distributors and service providers that have a strategic role in growing China s drug industry. CHNA ETF offers this global exposure all in the convenience of one security that trades in the United States. It tracks the LCHINA index. |
| Fund Profile |
| Fund Name |
Loncar China Biopharma ETF |
| Fund Exchange Ticker |
CHNA |
| Fund Sponsor |
Exchange Traded Concepts |
| Fund ISIN |
US26922A3703 |
| Net Expense Ratio |
0.79 % |
| Fund Inception Date |
14 August 2018 |
| Fund Legal Structure |
ETF (Open end fund) |
| Exchange |
NASDAQ |
| Listing Country Code |
US |
| Fund Investment Objective |
| ETF Type Specific |
Global or ExUS Equities - Industry Sector |
| Asset Class |
Equities (Stocks) |
| Index Linked |
Passive |
| Index Name |
Loncar China BioPharma Index |
| Index Provider |
Loncar Investments |
| Currency Hedged |
No |
| Inverse / Leveraged |
Not Applicable |
| Developed / Emerging |
Emerging Market Funds |
| Market Capitalization Range |
Broad Market / Multi-Cap |
| Growth Value |
Core / Blend |
| Continent |
Asia |
| Key Statistics |
| Return As of Date |
21 January 2021 |
| Asset Under Management |
14.48 Million (USD) |
| 1 Month Total Return |
22.02 % |
| Year To Date Return |
18.10 % |
| 1 Year Total Return |
46.68 % |
| 3 Year Annualized Total Return |
|
| NAV |
38.6035 |
| Share Outstanding |
375,000 |